Back to results
US 10,526,283 B2Granted
Prodrugs of dithiol mucolytic agents
AssigneeParion Sciences, Inc.
InventorsMichael Ross Johnson, William R. Thelin
Life of this patent
Estimating the term…
Abstract
Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): where the structural variables are as defined herein.
Claims24
A compound represented by formula Ia or Ib:
- wherein
- R1 and R2 are each, independently, hydrogen, lower alkyl, halogen or triflouromethyl;
- R3 and R4 are each, independently, hydrogen, lower alkyl, hydroxyl-lower alkyl, phenyl, (phenyl)-lower alkyl, (halophenyl)-lower alkyl, ((lower-alkyl)phenyl)-lower-alkyl, ((lower-alkoxy)phenyl)-lower-alkyl, (naphthyl)-lower-alkyl, or (pyridyl)-lower-alkyl;
- each R5 is, independently, hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, phenyl-lower alkyl-sulfonyl, OH, —(CH2)m—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —(CH2)n—NR7R7, —O—(CH2)m—NR7R10, —O—(CH2)m—NR7R7, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —O—(CH2)m—C(═O)NR7R10, —(CH2)n—(Z)g—R7, —O—(CH2)m—(Z)g—R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,
- -Link-(CH2)m-CAP, -Link-(CH2)n(CHOR8)(CHOR8)n-CAP, -Link-(CH2CH2O)m—CH2-CAP, -Link-(CH2CH2O)m—CH2CH2-CAP, -Link-(CH2)m—(Z)g-CAP, -Link-(CH2)n(Z)g—(CH2)m-CAP, -Link-(CH2)n—NR13—CH2(CHOR8)(CHOR8)n-CAP, -Link-(CH2)n—(CHOR8)mCH2—NR13—(Z)g-CAP, -Link-(CH2)nNR13—(CH2)m(CHOR8)nCH2NR13—(Z)g-CAP, -Link-(CH2)m—(Z)g—(CH2)m-CAP, -Link-NH—C(═O)—NH—(CH2)m-CAP, -Link-(CH2)m—C(═O)NR13—(CH2)m-CAP, -Link-(CH2)n—(Z)g—(CH2)m—(Z)g-CAP, or -Link-Zg—(CH2)m-Het-(CH2)m-CAP, with the proviso that at least one R5 group contains at least one basic nitrogen;
- each R7 is, independently, phenyl, substituted phenyl, lower alkyl phenyl or —CH2(CHOR8)m—CH2OR8;
- each R8 is, independently, hydrogen, lower alkyl, lower alkyl phenyl, —C(═O)—R1, glucuronide, 2-tetrahydropyranyl, or
- each R9 is, independently, —CO2R7, —CON(R7)2, —SO2CH3, —C(═O)R7, —CO2R13, —CON(R13)2, —SO2CH2R13, or —C(═O)R13;
- each R10 is, independently, —H, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, or —CH2—(CHOH)n—CH2OH;
- each Z is, independently, —(CHOH)—, —C(═O)—, —(CHNR7R10)—, —(C═NR10)—, —NR10—, —(CH2)n—, —(CHNR13R13)—, —(C═NR13)—, or —NR13—;
- each R11 is, independently, hydrogen, lower alkyl, phenyl lower alkyl or substituted phenyl lower alkyl;
- each R12 is, independently, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, —CH2(CHOH)n—CH2OH, —CO2R13, —C(═O)NR13R13, or —C(═O)R13;
- each R13 is, independently, hydrogen, lower alkyl, phenyl, substituted phenyl or —CH2(CHOR8)m—CH2OR8, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, —CH2—(CHOH)n—CH2OH, —(CH2)m—NR7R10, —(CH2)m—NR7R7, —(CH2)m—NR11R11, —(CH2)m—(NR11R11R11)+, —(CH2)m—(CHOR8)m—(CH2)mNR11R11, —(CH2)m—(CHOR8)m—(CH2)mNR7R10, —(CH2)m—NR10R10, —(CH2)m—(CHOR8)m—(CH2)m—(NR11R11R11)+, or —(CH2)m—(CHOR8)m—(CH2)mNR7R7;
- each R14 is, independently, —C(═O)—R7, —C(═O)-lower alkyl, or an amino acyl of the natural configuration;
- each g is, independently, an integer from 1 to 6;
- each m is, independently, an integer from 1 to 7;
- each n is, independently, an integer from 0 to 7;
- each -Het- is, independently, —N(R7)—, —N(R10)—, —S—, —SO—, —SO2—;
- —O—, —SO2NH—, —NHSO2—, —NR7CO—, —CONR7—, —N(R13)—, —SO2NR13—, —NR13CO—, or —CONR13—;
- each Link is, independently, —O—, —(CH2)n—, —O(CH2)m—, —NR13—C(═O)—NR13—, —NR13—C(═O)—(CH2)m—, —C(═O)NR13—(CH2)m−, —(CH2)n—(Z)g—(CH2)n—, —S—, —SO—, —SO2—, —SO2NR7—, —SO2NR10—, or -Het-;
- each CAP is, independently
- with the proviso that when any —CHO8— or —CH2OR8 groups are located 1,2- or 1,3- with respect to each other, the R8 groups may, optionally, be taken together to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
- or racemates, enantiomers, diastereomers, tautomers, polymorphs, pseudopolymorphs or pharmaceutically acceptable salts thereof.
20 more elements
A composition containing a pharmaceutically acceptable carrier, hypertonic saline and a compound represented by the formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.